Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
đźš« GENESIS SOLD OUT
DAPAPAY COMING ›

Business

The Odyssey boosts IMAX ticket sales and revenue

Published

on

The Odyssey boosts IMAX ticket sales and revenue

The Odyssey

Source: Universal Pictures

Christopher Nolan’s “The Odyssey” is racking up box office dollars for IMAX and fueling investor confidence that the company will reach record ticket sales in 2026.

Advertisement

Shares of IMAX jumped more than 8% on Thursday after the company reported it was still on track to deliver a record $1.4 billion in global box office this year. Wall Street had worried that when Netflix and Greta Gerwig’s “Narnia: The Magician’s Nephew” was pushed from its November release date to February 2027, that IMAX would not be able to reach that guidance.

Universal’s “The Odyssey” is easing those fears. Over its opening weekend, the film generated $52 million in global box office for IMAX. The company’s locations represented less than 1% of total screens but a whopping 20% of the film’s worldwide debut.

“The Odyssey” opening was 47% higher than Nolan’s previous film “Oppenheimer.” The biopic hauled in more than $190 million via IMAX throughout its run in 2023.

And momentum for “The Odyssey” has showed few signs of slowing. The film secured another $11 million on Monday and $10.6 million on Tuesday — the best Tuesday performance of all time for the company, according to IMAX CEO Rich Gelfond, who spoke to investors on an earnings call Thursday.

Advertisement

“Our presales for the second weekend would qualify on its own as one of our biggest opening weekends ever,” he said. “These numbers help prove that we’re just getting warmed up.”

Still to come to global IMAX screens this year is Sony and Marvel’s “Spider-Man: Brand New Day;” Zach Cregger’s take on “Resident Evil;” Tom Cruise’s newest feature “Digger;” “Godzilla Minus One;” David Fincher’s “The Adventures of Cliff Booth,” which stars Brad Pitt and is based on Quentin Tarantino’s “Once Upon a Time in Hollywood;” and Paramount’s “Street Fighter.”

Then Warner Bros. and Denis Villeneuve’s “Dune: Part Three” will cap off the year. The first Dune film generated $61 million in IMAX theaters during the tail end of the pandemic and “Dune: Part Two” secured $147 million globally.

“Our momentum continues to translate into demand from our exhibition partners,” Gelfond said.

Advertisement

The company installed 38 IMAX systems globally during the second quarter, up from 36 during the same period a year prior. This is the highest number of installations in the second quarter in a decade, Natasha Fernandes, IMAX’s chief financial officer, told investors during Thursday’s earnings call. Nineteen systems were installed in the first quarter and the company is on pace to have 160 to 175 installations by the end of 2026.

IMAX currently has a backlog of 421 contracts to build screens.

“We continue to see tremendous runway for our global expansion, and we continue to innovate in ways that make IMAX even more valuable to creators, studios, exhibitors and audiences alike,” Gelfond said. “This is an incredibly exciting time for our business.”

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Luka Doncic Says Watching LeBron James Prepare for Games Taught Him the Most During Their Time Together

Published

on

LeBron James / Luka Doncic

Luka Doncic says the most valuable lesson he took away from playing alongside LeBron James with the Los Angeles Lakers had little to do with anything that happened during games themselves, and everything to do with what James does long before tipoff.

Doncic made the comments during an appearance on James’ “Mind the Game” podcast, co-hosted with two-time MVP Steve Nash, reflecting on his time as a teammate of the four-time NBA MVP since arriving in Los Angeles via a blockbuster midseason trade in February 2025.

What Doncic learned

Asked what stood out most about playing alongside James, Doncic pointed directly to James’ preparation habits rather than his on-court production. “First of all, off the court, you know, all the things he does just to be ready for the game. And obviously on the court, everybody knows what kind of player he is,” Doncic said.

Advertisement

When pressed for a specific example, Doncic described being genuinely surprised by how early James arrives at the arena before games. “He shows up like 10 hours before the game. … I came to the arena, he was already done working out. I was like, what?” Doncic said.

A trade that reshaped the Lakers

Doncic joined the Lakers in a trade that stunned the NBA when it was announced, sending him from the Dallas Mavericks to Los Angeles in exchange for Anthony Davis just weeks before the 2025 trade deadline. At the time, Doncic was already regarded as one of the league’s most talented offensive players, but questions persisted about his conditioning and defensive effort, criticism that had followed him for much of his career in Dallas.

Those questions carried into his first partial season with the Lakers, which ended with a first-round playoff exit at the hands of the Minnesota Timberwolves. Entering the following offseason, Doncic faced pressure to reshape his conditioning heading into a full season alongside James.

Advertisement

A dramatically improved season

Doncic answered that challenge. Last summer, he dropped significant weight and reported to training camp in markedly better shape, a transformation that carried through into one of the best individual seasons of his career. Over the 2025-26 season, Doncic averaged 33.5 points, 7.7 rebounds, 8.3 assists and 1.6 steals per game while leading the Lakers to a 53-29 record and the fourth seed in the Western Conference.

Doncic’s improved conditioning appeared to pay off on both ends of the floor. He earned Western Conference Player of the Month honors in both January and March, and his defensive engagement, long a target of criticism, showed clear signs of improvement over the course of the season.

A season cut short by injury

Advertisement

Despite that strong individual campaign, Doncic’s season ended prematurely when he suffered a season-ending hamstring strain on April 2, forcing him to miss the Lakers’ playoff run entirely. The injury denied Doncic the chance to build on his regular-season performance on basketball’s biggest stage, a frustrating conclusion to what had otherwise been a breakout year in Los Angeles.

Despite the injury setback, Doncic has expressed optimism about the Lakers’ direction heading into next season. He recently said he is “excited” about the team’s retooled roster, and separately described himself as “very excited” for the start of the new campaign, signaling confidence in Los Angeles’ outlook even after the disappointment of missing the postseason.

A veteran mentor with a long track record

James, now widely regarded as one of the most disciplined professional athletes in terms of body maintenance and game preparation, has served as a mentor figure for a long line of younger Lakers teammates over his tenure with the franchise. His approach to recovery, nutrition and physical conditioning has been credited by numerous teammates and opponents alike as a significant factor in his ability to remain a high-level performer well into his 20th NBA season.

Advertisement

Doncic’s account of James’ pregame routine, arriving roughly 10 hours before tipoff and completing his workout before most players have even reached the arena, reflects a level of preparation that has become something of a defining trait associated with James throughout his career, one that Doncic suggested directly influenced his own approach to conditioning heading into last season.

At 27 years old, Doncic appears to be entering what could become an especially productive stretch of his career, having paired his existing offensive brilliance with a newly improved level of physical conditioning during his first full season in Los Angeles. With James continuing to serve as both a teammate and, by Doncic’s own account, something of a professional example to follow, the Lakers will be looking for Doncic to build further on last season’s individual success once healthy for training camp.

Whether that improved conditioning and preparation habits translate into deeper playoff success for the Lakers next season remains to be seen, particularly given how last season ended prematurely due to injury. But Doncic’s comments on James’ podcast suggest that, beyond any statistical or on-court influence, playing alongside James has already reshaped how Doncic approaches the less visible parts of being a professional athlete, the preparation that happens long before any game begins.

Advertisement
Continue Reading

Business

SK Hynix’s US-Listed Shares Jump 4.5% as Alphabet’s Bigger AI Spending Forecast Lifts Global Chipmakers

Published

on

SK Hynix ADR Plunges Nearly 8% to $162 as Wild

SK Hynix’s U.S.-listed shares climbed further Thursday, extending a volatile but largely upward run since the South Korean memory chipmaker’s record-breaking Nasdaq debut two weeks ago, as renewed optimism about artificial intelligence infrastructure spending lifted chip stocks broadly.

SK Hynix’s American depositary receipts, trading under the ticker SKHY, stood at $172.70 as of 12:55 p.m. Eastern time, up $7.43, or 4.50%, on the day. The gain builds on a stretch of significant volatility for the newly listed shares, which have swung sharply in both directions since their Nasdaq debut on July 10.

What’s driving Thursday’s gains

Thursday’s rally was fueled largely by Alphabet’s latest earnings report, released after Wednesday’s market close, in which the Google parent company raised its 2026 capital expenditure forecast to a range of $195 billion to $205 billion, up from its earlier guidance of $180 billion to $190 billion. Alphabet also reported that Google Cloud revenue jumped 82% to $24.8 billion in the second quarter, reinforcing investor confidence in continued heavy spending on AI infrastructure. Alphabet Chief Financial Officer Anat Ashkenazi said demand continues to exceed supply. “The demand still outpaces that investment,” Ashkenazi said.

Advertisement

That spending signal rippled through the broader semiconductor sector Thursday. Shares of Micron Technology rose roughly 3% at the start of U.S. trading, while SK Hynix’s ADR gained more than double that percentage, reflecting the additional volatility built into the newly listed depositary receipts, which trade with a capped conversion structure relative to the company’s Seoul-listed shares.

A record-breaking Nasdaq debut

SK Hynix made history earlier this month when it raised $26.5 billion in its American depositary receipt offering, the largest first-time share sale by a foreign company ever recorded in the United States, surpassing the $25 billion Alibaba raised in its 2014 listing. The company sold 177.9 million ADRs at $149 each, with each ADR representing one-tenth of a common share traded in Seoul. The offering was more than seven times oversubscribed, according to Bloomberg, drawing interest from long-only generalist funds, technology-focused funds, sovereign wealth funds and globally focused Asia investors.

Shares jumped 13% on their first day of trading July 10, closing at $168.01. SK Hynix Chairman Chey Tae-won described the milestone in personal terms during an interview with CNBC at the time. “It’s a kind of dream, and now it’s a dream come true,” Chey said, adding that demand for the company’s high-bandwidth memory chips used in AI applications showed no signs of slowing. “The demand is enormous, exponentially, so I don’t really see” evidence that demand is shrinking, he said.

Advertisement

A volatile first two weeks

The stock’s performance since its debut has been anything but steady. Just days after listing, the ADRs tumbled 9.3% in a single session as a record selloff in South Korean equities spilled into U.S. trading, before more than recovering with a 27% gain the following day. That swing pushed the ADR’s premium over SK Hynix’s Seoul-listed common shares to as high as 51% at one point, far above the roughly 3% premium at which the securities were originally priced.

More recently, the premium has moderated but remained elevated. As of Wednesday’s session, SK Hynix’s ADR traded at a calculated premium of roughly 34.5% over its Seoul shares once adjusted for currency exchange rates, according to market analysis, reflecting continued strong U.S. investor demand relative to the underlying Korean-listed stock.

Why investors are betting on SK Hynix

Advertisement

SK Hynix is the world’s leading producer of high-bandwidth memory, or HBM, a specialized and complex form of computer memory created by stacking multiple layers of traditional memory chips together, which has become essential for powering AI accelerator chips made by companies including Nvidia. That positioning has fueled a dramatic rise in the company’s valuation, with SK Hynix’s stock climbing more than sevenfold over the past year amid a global shortage of AI-grade memory chips and sharply rising prices.

The company’s aggressive expansion plans, including continued investment in its Yongin HBM production hub in South Korea and a packaging plant in Indiana, were central to its rationale for pursuing the U.S. listing, giving SK Hynix expanded access to American capital markets to fund its buildout.

What’s ahead for the stock

SK Hynix is scheduled to report second-quarter earnings on July 29, a report that will offer investors their first detailed look at the company’s financial performance since its Nasdaq listing. Analysts’ preliminary consensus estimates project earnings per share of 71,211 won, a figure roughly 3.6% higher than estimates from a month earlier, reflecting continued upward revisions to the company’s expected performance heading into the report.

Advertisement

Separately, SK Hynix moved this week to deny media reports suggesting it was in talks to acquire Intel’s Ohio semiconductor manufacturing facility, a report that had circulated amid broader speculation about consolidation and partnership activity across the chip industry.

A broader rally across Asian chip stocks

SK Hynix’s gains Thursday came alongside broader strength in South Korea’s stock market. The company’s Seoul-listed shares finished 4.86% higher at 1.919 million won, contributing to gains across the country’s benchmark index, with fellow chipmaker Samsung Electronics also among the beneficiaries of the renewed optimism around AI-related capital spending following Alphabet’s earnings report.

With SK Hynix’s earnings report just days away, investors are likely to watch closely for further confirmation of the demand trends that have driven the stock’s dramatic rise over the past year, along with any additional detail on the company’s HBM production capacity and pricing power heading into the second half of 2026. Given the elevated premium the ADRs continue to command over their Seoul-listed counterpart, some analysts have cautioned that a narrowing of that gap remains a possibility depending on how the upcoming earnings report and broader market sentiment around AI spending evolve in the weeks ahead.

Advertisement
Continue Reading

Business

Big bosses reveal the secret to getting hired

Published

on

woman with long dark hair looks at her phone, with an expression of joy on her face.

Business leaders share their best career advice and the qualities they look for when recruiting new staff.

Continue Reading

Business

Waaree Renewable shares slide 7% despite 34% YoY surge in Q1 profit. What’s spooking investors?

Published

on

Waaree Renewable shares slide 7% despite 34% YoY surge in Q1 profit. What's spooking investors?
Shares of Waaree Renewable, the EPC arm of the Waaree Group, dropped 7% on Thursday after the company announced its Q1 FY27 earnings, reporting a 34% year-on-year (YoY) rise in net profit to nearly Rs 116 crore.

The shares of the company dropped to Rs 951 apiece on Thursday, the lowest level seen since June 12. While consolidated net profit grew 34% from Rs 86 crore reported in Q1 of the previous financial year, it fell around 26% sequentially from the Rs 157 crore reported in Q4 of FY26.

Revenue from operations also increased over 53% YoY to Rs 924 crore in Q1 FY27 from Rs 603 crore reported in the corresponding quarter of FY26, but fell more than 16% quarter on quarter (QoQ) from Rs 1,102 crore reported in the previous quarter (Q4 FY26). “We believe the true measure of business strength lies in sustained YoY growth,” the company said.

Waaree Renewable’s EBITDA grew nearly 48% YoY to Rs 173 crore, while EBITDA margin declined to 18.77% in Q1 FY27 from 19.49% in Q1 FY26. The company said it has been expanding its capabilities across adjacent segments beyond its core renewable EPC business, adding that its recent acquisition of Associated Power Structures (APSPL) strengthens its presence in the transmission and distribution (T&D) space.

Advertisement

What Waaree Renewable’s management said

The global business environment continues to face multiple challenges, including geopolitical tensions, tariff uncertainties, supply chain adjustments and regional conflicts, said Waaree Renewable CFO Manmohan Sharma. “Despite these headwinds, we are pleased to begin FY27 on a strong note, with consolidated revenue for Q1 FY27 at Rs 924.25 crores compared to Rs 603.19 crore in Q1 FY26, reflecting a robust growth of 53.23%. This performance was driven by steady execution across our EPC portfolio, efficient resource deployment, and a sustained focus on disciplined project delivery,” he added.
The executive said that the company’s acquisition of 55% stake in Associated Power Structures strengthens its capabilities in transmission and distribution (T&D), enabling it to offer integrated solutions while continuing to expand renewable EPC business in a disciplined and scalable manner.
Also Read | IndusInd Bank shares fall 5% despite 72% YoY Q1 profit surge. Why analysts remain bullish?
“Backed by a healthy unexecuted order book of Rs. 5,300+ crores, Waaree Renewable remains well positioned for sustained growth, supported by expanding O&M capabilities. Supported by a strong execution track record and expanding capabilities, we remain confident in our long-term growth strategy. We will continue to focus on disciplined execution, operational excellence, and delivering sustainable value to our stakeholders,” Manmohan Sharma further said.

Waaree Renewable share price
Waaree Renewable shares debuted on the BSE SME index in August 2012 with an issue size of Rs 5 crore. In 2019, the stock migrated to the main exchange after the company grew both in market capitalisation as well as sales.

The stock has delivered massive returns of more than 2,870% in the past five years, but have fallen over 14% in one year. While the stock has gained more than 9% in six months, it is down 3% in one month and 5% in the past five days. The company currently has a market capitalisation of Rs 10,015 crore.

Also Read | Alphabet’s quarterly earnings beat Wall Street estimates, but here’s what is spooking investors

Advertisement

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Continue Reading

Business

Cyclospora outbreak tests CDC, RFK Jr. response

Published

on

Cyclospora outbreak tests CDC, RFK Jr. response

Robert F. Kennedy Jr., US secretary of Health and Human Services (HHS), during a celebration at the Health and Human Services (HHS) headquarters in Washington, DC, US, on Thursday, Jan. 8, 2026.

Kent Nishimura | Bloomberg | Getty Images

Robert F. Kennedy Jr. took the helm of the U.S. Department of Health and Human Services last year promising to overhaul the U.S. food system and restore confidence in the agencies that oversee it.

Advertisement

The secretary of the Department of Health and Human Services now faces one of his biggest tests yet, as the country tries to contain an outbreak – or potentially multiple outbreaks – of foodborne illness. Two months and thousands of cases of cyclosporiasis later, it looks like the nation’s already fragile system is faltering.

Experts have long said the U.S. is underprepared to rein in foodborne outbreaks. But after the Trump administration slashed key officials — from federal employees who investigate the source of illnesses to those who share information with the public — Kennedy appears to face an even more daunting task to contain the parasite and build trust in the administration’s response.

“It is difficult to quantify precisely, but it is clear that the cuts to federal funding over the past year or so have reduced our capacity to respond to outbreaks like this,” said Craig Hedberg, co-director of the Minnesota Integrated Food Safety Center of Excellence.

Kennedy earlier this week defended the handling of an outbreak of cyclosporiasis that has sickened at least 7,000 people in Michigan alone. (The official count from the Centers for Disease Control and Prevention, which has lagged behind state tallies, sits at nearly 4,200 cases). Kennedy said the ongoing outbreak of cyclosporiasis is “under control,” contending criticisms that agency cuts have hampered the investigation are “invalid.”

Advertisement
Dr. Scott Gottlieb on cyclospora outbreak: The false positive test result is 'a red herring'

The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention have narrowed their focus to shredded iceberg lettuce from Taylor Farms, a produce supplier for a range of restaurants and grocers. The FDA over the weekend said lettuce from the company tested positive for cyclospora, the parasite that causes the explosive diarrhea. The agency later walked that back, saying it was a false positive.

Donald Schaffner, chair of food science at Rutgers University, said he’s never seen such a reversal before and called it a “pretty big screw up.” Still, one former senior FDA food official said the agency was right to publicize the positive test because if it turned out to be a true positive, delaying the announcement could have caused more people to fall ill. And regardless of the test result, the agencies still see the lettuce as a likely culprit.

The about face, and the confusion it created over whether regulators still suspected the Taylor Farms lettuce was tied to the outbreak, underscored the difficulty Kennedy faces in trying to restore public confidence.

HHS spokesperson Emily Hilliard in a statement to CNBC said the FDA has been transparent with Taylor Farms throughout the investigation and the corrected lab result doesn’t change the agency’s findings.

Former federal health officials and independent food safety experts say they see the cyclospora response as a prime example of a system that’s long been underfunded and overstrained, leaving the U.S. vulnerable to these kinds of outbreaks. And they fear budget cuts, policy delays and personnel turnover are exacerbating an already delicate situation.

Advertisement

In response, Hilliard said regulators have “mounted a robust, science-based response to this outbreak, working closely with health departments in all 50 states, rapidly identifying known sources, and ensuring Americans have the information they need to protect themselves.”

She added, “FDA and CDC continue working together to use every available public health tool to identify additional sources of the outbreak and inform swift public health action.”

More CNBC health coverage

Why the cyclospora outbreak is hard to track

Technician holding a specimen container with stool sample for cyclospora test.

Md Babul Hosen | Istock | Getty Images

Advertisement

Cyclospora is a parasite that’s trickier to track than some other pathogens. Parasites don’t grow outside the human body, making it harder to test for them and link cases to each other. Cyclospora tests are prone to false positives because the process for conducting them can sometimes make it look like there’s a parasite in the sample when there’s not, Schaffner said.

Some experts said the Trump administration funding cuts make that tall task even tougher.

Dr. Daniel Jernigan, former director of the CDC’s National Center for Emerging and Zoonotic Infectious Diseases, pointed to the CDC’s Division of Parasitic Diseases and Malaria losing $40 million in funds from the U.S. Agency for International Development after the Trump administration dismantled the organization. The agency anticipates recovering some funds, though it would represent one-quarter of the money it used to receive from USAID, according to Jernigan.

Jernigan estimates the group has lost about one-quarter of its staff because of the budget cuts. Some of those employees worked on other parasitic diseases like malaria, but would typically be tapped to help respond in an emergency situation like this one, he said. As a result of the cuts, CDC is trying to move the parasitic diseases groups to the Division of Foodborne, Water and Environmental Diseases, which Jernigan says is a good thing for optimizing foodborne disease investigation and control.

Advertisement

“At the beginning of this response, the cuts because of the USAID [funding] made that division less capable of responding fast, and that’s not rocket science,” Jernigan said. “Just fewer people, you don’t have the reserve.”

HHS’ Hilliard said the funds were dedicated to international activities and were not used to support the CDC’s domestic foodborne disease response. She added that Trump’s proposed fiscal year 2027 budget proposes a $33 million increase for food safety activities.

Jernigan suggests increasing that budget would help improve the agency’s ability to respond to such outbreaks. CDC funding for food safety hasn’t seen a meaningful increase since 2014, according to an analysis from George Washington University’s Institute for Food Safety and Nutrition Security.

This fiscal year, the CDC’s budget for food safety is $74 million, up $2 million from last year, according to the agency’s operating plan. That food safety sum represents about 10% of funds for the CDC’s emerging and zoonotic infectious diseases work.

Advertisement

CDC’s FoodNet, or the Foodborne Diseases Active Surveillance Network, stopped mandatory reporting for six of eight pathogens it previously monitored, including cyclospora, because there hasn’t been enough money forthe work, something experts say is a result of chronic underfunding of food safety. That program tracks foodborne illness outbreaks over time rather than identifying new outbreaks.

Kennedy earlier this week said cuts in the FoodNet program were for “redundant surveillance.”

At the FDA, the agency’s budget for food has long been a fraction of centers that oversee regulation of drugs and devices. This year, the food center’s $1.17 billion budget represents about 17% of the agency’s roughly $7 billion in total program level spending.

Food funding has lagged other areas in part because it disproportionately comes from congressional appropriations, whereas money for other centers, including those that oversee prescription drugs and tobacco products, largely comes from fees the industry pays for reviews of applications.

Advertisement

The so-called Department of Government Efficiency, which oversaw massive federal layoffs last year, spared the FDA’s foodborne illness outbreak personnel from sweeping cuts, according to the former senior FDA official. The FDA’s main press office was gutted, stripping the agency of outbreak communications expertise.

Some contend the FDA’s messaging around the false positive sowed confusion about the investigation and how consumers should respond.

Ellen Shumaker, director of outreach for Safe Plates at North Carolina State University, said the FDA’s recall communications have needed modernization for some time. She said the agency needs to give clear communications to consumers, telling them in plain language what concrete steps they can take. She added that the agency needs to more quickly classify how severe a recall is.

In this case, the FDA said illnesses started on May 17, yet it didn’t issue a public notice until July 16, a timeline that suggests the response was slower than expected, said Frank Yiannas, former deputy commissioner of food policy and response at the FDA. One measure that he and other food safety experts say could have helped accelerate the response was the FDA’s Food Traceability Rule, which was supposed to go into effect this year but was delayed by two-and-a-half years. The policy was designed to help the FDA quickly see where a food came from to respond to foodborne illness outbreaks.

Advertisement

Kennedy has repeatedly promised to rebuild trust in the CDC following the Covid-19 pandemic and restore its focus on infectious disease, and the cyclospora response gives him a chance to display any improvements to the agency’s handling of a crisis. So far, experts said they have not seen the response get much better.

How funding cuts affected food safety agencies

State and local health departments are also feeling the effects of the Trump administration’s cuts. A May analysis from the Congressional Research Service found the administration terminated $5.78 billion in CDC grants to states.

Sarah Sorscher, director of regulatory affairs at the Center for Science in the Public Interest, said states use the block grants to fund epidemiologists and other specialists involved in investigating outbreaks.

In Kentucky, the group that’s primarily responsible for conducting case interviews for foodborne illnesses has experienced a 30% to 50% decrease in staffing due to a reduction in federal grant funds, according to a spokesperson for the state’s department of public health. The state anticipates more staff reductions next year due to additional cuts to federal grants next year.

Advertisement

Even so, one state hit hard by the outbreak said it has received federal help. The Ohio Department of Health requested federal help for the cyclospora investigation and will host several of the CDC’s Epidemic Intelligence Service officers this week to assist, a spokesman told CNBC. The state agency has requested help from the CDC in prior responses, including a measles outbreak in 2022 and the East Palestine train derailment in 2023.

In the meantime, more people are falling ill. The CDC has received reports of more than 4,000 laboratory confirmed cases and is aware of more than 7,400 additional cases, many of them in Michigan and Ohio, that haven’t been confirmed by a lab test yet.

And on Wednesday, the FDA reported a new outbreak among dozens of people linked to a product that hasn’t been identified yet, meaning the health agencies have even more leads to investigate.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Advertisement
Continue Reading

Business

Earnings call transcript: Colonial SFL confirms H1 2026 growth and guidance

Published

on


Earnings call transcript: Colonial SFL confirms H1 2026 growth and guidance

Continue Reading

Business

R&B Singer Nivea Reveals Leukemia Diagnosis at 44 and Credits Faith for New Perspective

Published

on

Nivea

R&B singer Nivea has revealed that she is battling leukemia, sharing details of her diagnosis and treatment during a recent interview while expressing deep gratitude for the perspective the experience has given her.

The 44-year-old performer, known for her early 2000s hits, disclosed the news on the “Cadillac Chronicles” interview series. When asked what she was thankful for at the moment, she responded candidly about her health journey.

“I was diagnosed with leukemia earlier this year, and I am so grateful to God,” she said. “I’ve been going through treatment and everything is going great so far. And I expect it to continue. Amen. Amen. Amen. And I’m very grateful for life. It’s so clichĂ© to say, you know, you don’t know the time nor the hour, and it’s true.”

Nivea, whose full name is Nivea B. Hamilton, noted that the diagnosis shifted her outlook significantly. “It just helped me put a lot of things in perspective,” she added. “And I live in gratitude like religiously, and I’m just grateful for everything. I’m doing things I want to do. I’m definitely back into my music.”

Advertisement

She also shared that she has returned to school to study audio engineering, a longtime interest. “I’ve always wanted to learn how to engineer, and mix and engineer in particular,” she said. “But, in general, just doing all the things, honey. Loving all my children and just being grateful. Taking every opportunity that comes my way.”

When asked about the biggest lesson she has learned, Nivea emphasized presence and appreciation. “Definitely don’t take anything for granted,” she said. “Like, I definitely lived in my younger years. The days just flew by, and I was just doing what I was doing. I don’t know. It’s kind of like you don’t recognize the short time that we do have here, and how everything is … I’ve always noticed the beauty in everything, though, I will say that. But, to be more present in the moment is definitely something I’ve learned. This time will never occur again. Being more present in the moment. Counting the blessings. Being more grateful.”

She continued by discussing the power of focus and positivity. “The universe or God or whatever you want to call it, your brain will find the things you focus on,” she said. “You know where the mind goes energy goes. So I just try to think of positive things. I’m a very optimistic person.”

Nivea rose to prominence in the early 2000s with her self-titled debut album released in 2002. Her single “Don’t Mess with My Man” earned a Grammy nomination for Best R&B Performance in 2003. She has released four albums in total, with her most recent being “Mirrors” in 2019.

Advertisement

Fans and supporters have responded with messages of encouragement following the revelation. Many recalled her previous health challenges, including a postpartum stroke she experienced years earlier, and praised her resilience and continued creative pursuits.

Leukemia is a cancer of the blood-forming tissues that can affect people of various ages. Treatment approaches often include chemotherapy, targeted therapies or other medical interventions depending on the specific type and stage. Nivea indicated her treatment has progressed positively so far and expressed optimism about continued improvement.

In the interview, the singer repeatedly returned to themes of faith and gratitude. She framed the diagnosis not solely as a medical challenge but as a catalyst for living more intentionally and pursuing long-held goals such as music production skills.

Nivea’s career has spanned more than two decades, with her early work establishing her as a notable voice in contemporary R&B. Beyond recording, she has remained connected to music through performances and personal projects. Her decision to study audio engineering reflects a desire to expand her role behind the console as well as in front of the microphone.

Advertisement

The timing of the public disclosure comes as she continues treatment while balancing family life and creative ambitions. She spoke warmly about her children and the importance of seizing opportunities, suggesting a renewed sense of purpose.

Music industry observers noted that artists often share health journeys to raise awareness and connect with fans on a human level. Nivea’s openness aligns with a broader trend of public figures discussing medical challenges candidly.

Her comments about living in the present and avoiding complacency resonated with many who have followed her career. The singer acknowledged that time can pass quickly during periods of activity and success, and that intentional presence requires deliberate effort.

Nivea’s story also highlights the role of spiritual practice for some individuals facing serious illness. She repeatedly credited God for her progress and expressed repeated affirmations of gratitude and expectation for continued positive outcomes.

Advertisement

As she continues treatment, Nivea appears focused on both recovery and personal growth. Her return to music and enrollment in audio engineering courses suggest an active approach to the future rather than a pause.

Supporters have encouraged her publicly, revisiting her catalog of songs and celebrating her determination. The response underscores the connection many fans feel with artists who share vulnerable moments.

Leukemia awareness efforts often emphasize early detection and the importance of medical care. While Nivea did not detail specific symptoms or the precise form of the disease, her willingness to discuss the diagnosis may prompt conversations among listeners about health monitoring.

In the interview, she balanced realism about the uncertainty of life with a clear sense of optimism. The repeated “Amen” and statements of gratitude framed her outlook as one rooted in faith and expectation of positive results.

Advertisement

Nivea’s career trajectory includes both commercial success and periods of relative quiet. Her 2019 album “Mirrors” marked a later chapter, and recent comments indicate she is re-engaging with creative work amid her health management.

Family remains a central theme in her reflections. Mentions of loving her children and prioritizing meaningful experiences suggest that personal relationships have taken on heightened importance.

The broader context of her revelation includes the physical and emotional demands of cancer treatment. Many patients describe shifts in priorities, relationships and daily routines. Nivea’s account aligns with those common experiences while remaining distinctly personal.

She has not indicated any interruption in her long-term plans. Instead, the diagnosis appears to have accelerated certain pursuits, including formal training in engineering skills she had long desired.

Advertisement

Industry colleagues and fellow artists have in the past offered support during similar disclosures. While specific statements from peers were not detailed in the initial interview, the overall response from the public has been one of solidarity.

Nivea’s emphasis on positivity and mental focus reflects practices many people adopt during difficult periods. She described intentionally directing her thoughts toward constructive and hopeful outcomes.

As treatment continues, updates on her progress will likely be of interest to fans who have followed her career. For now, her message centers on gratitude, faith and living intentionally.

The singer’s openness provides a window into how one public figure is navigating a serious diagnosis while maintaining creative and personal goals. Her words underscore both the challenges and the potential for renewed purpose that can accompany such experiences.

Advertisement

Nivea’s story continues to unfold as she balances medical care with music, education and family. The perspective she described—valuing presence, counting blessings and maintaining optimism—remains central to the account she shared.

Fans and observers will continue to follow her journey with interest and support. Her early hits introduced her to a wide audience, and her current reflections offer a more personal dimension to her public presence.

In speaking about the diagnosis, Nivea chose language of gratitude and expectation rather than solely focusing on difficulty. That framing has defined the public conversation around her revelation.

The interview captured a moment of vulnerability paired with resilience. As she continues treatment and creative work, her emphasis on living fully in the present serves as a consistent theme.

Advertisement

Nivea’s career and personal narrative now include this chapter of health management and personal growth. The response from listeners reflects appreciation for her candor and determination.

Continue Reading

Business

Free Agent Wide Receiver Tyreek Hill Says He Still Has ‘No Power’ in Left Leg 10 Months After Injury

Published

on

Tyreek Hill

Free agent wide receiver Tyreek Hill said in a new rehabilitation video posted Wednesday that he still lacks strength in his surgically repaired left leg, roughly 10 months after suffering a dislocated knee and multiple torn ligaments that ended his 2025 season and, so far, kept him off any NFL roster.

Hill, 32, shared the update in a video posted to his YouTube channel, offering fans and prospective teams their most direct look yet at where his recovery stands as NFL training camps begin opening around the league this week.

What Hill said about his recovery

Hill described his current physical state in blunt terms. “So it’s about 10 months after doing two surgeries,” Hill said in the video. “My left leg is the one that I injured. I have no power in my left leg at all, so I’m trying to regain all the power back in my left leg. But it’s one day at a time.”

Advertisement

He detailed the specific rehabilitation work he has been doing to rebuild strength in the injured leg. “I’ve been activating the quads, the glutes, the hamstrings, the calves. I’ve been doing all the stability work, all the mobility work I need to get my knee back right,” Hill said. Despite the lack of power he described, Hill struck an optimistic tone about his overall progress, declining to commit to a specific timetable for a return. “I ain’t going to tell you what my timeline is, but timeline looking real good right now, man,” he said.

How the injury happened

Hill dislocated and tore multiple ligaments in his left knee, including his ACL and LCL, during the Miami Dolphins’ 27-21 win over the New York Jets on Sept. 29, 2025. He underwent surgery the following day and later had an additional procedure on his LCL this past February. Hill said doctors initially told him he “might not be able to walk again” following the injury, underscoring the severity of the damage even as he now works to regain strength and mobility.

In the video, Hill is shown performing a range of exercises as part of his rehabilitation, including work in a swimming pool, resistance band training, and some light running and jumping on turf and a basketball court, activities that suggest continued progress even as he says explosive power in the leg has not yet returned.

Advertisement

A free agent since February

Miami released Hill in February after four seasons with the franchise, making him a free agent for the first time in his career. He had appeared in just four games during the 2025 season before the injury, recording 21 catches for 265 yards and one touchdown. As of this week, no team has signed Hill, and there has been no strong indication throughout the offseason that any franchise is close to doing so, given the uncertainty surrounding his recovery timeline and long-term explosiveness following such a severe injury.

Medical experts following Hill’s situation have offered a cautious outlook on his prospects for a full return to his prior form. Dr. David Chao, founder of Sports Injury Central and a former team physician for the San Diego Chargers, noted the severity of the type of injury Hill suffered when assessing his outlook, pointing to the case of NFL quarterback Teddy Bridgewater, who missed a year and a half after dislocating his knee. Chao noted that Hill’s injury involved more than just a torn ACL, reflecting the broader ligament damage that has complicated his recovery.

A decorated career, now in question

Advertisement

Hill enters this uncertain stretch of his career as one of the most accomplished wide receivers of his generation. Since entering the NFL in 2016, he ranks second among all wide receivers in career receiving yards with 11,363, third in touchdowns with 83, and fifth in receptions with 819. He has earned eight Pro Bowl selections and was named First Team All-Pro five times across his 10 NFL seasons split between the Kansas City Chiefs and Dolphins. Hill also won Super Bowl LIV with the Chiefs during the 2019 season.

His best individual season came in 2023, his second year in Miami, when he led the entire NFL in both receiving yards, with 1,799, and receiving touchdowns, with 13, cementing his reputation as one of the league’s most explosive offensive weapons before last season’s injury.

A message of gratitude

Hill closed his video update by thanking the medical staff who have supported him throughout his recovery process. “Shout out to all the doctors I’ve seen. Shout out to the Miami Dolphins training crew,” he said. “They’ve been great. Everybody has been great throughout this process.”

Advertisement

With NFL teams beginning to report for training camp this week, Hill’s continued free agency, and the uncertainty surrounding when, or whether, he will regain the explosive speed that defined his career, leaves his football future genuinely in question heading into the 2026 season. While Hill’s own comments suggest cautious optimism about his overall trajectory, his acknowledgment that he still lacks power in his surgically repaired leg 10 months post-injury indicates that any potential return to an NFL roster, let alone a return to his prior level of play, remains, by his own account, still some distance away.

Continue Reading

Business

McCormick-Unilever Foods merger taking shape

Published

on

McCormick-Unilever Foods merger taking shape

Combined business to have four commercial divisions.

Continue Reading

Business

Honda teases new American-built midsize pickup truck

Published

on

Honda teases new American-built midsize pickup truck

2026 Honda Ridgeline pickup truck.

Courtesy HondaHonda,

Honda Motor on Thursday confirmed a next-generation model of its Ridgeline pickup truck will be produced in the U.S. following a temporary production stoppage later this year.

Advertisement

The future of the midsize pickup truck has been in flux amid reports that there could be a production pause coming due to the vehicle not meeting California emissions regulations.

The Japanese automaker on Thursday said there will be a temporary production stoppage for the pickup truck later this year at the Alabama plant that produces the vehicle, with assembly returning to the facility within two years, likely in 2028.

“The goal is to continue to serve those customers who’ve been loyal to the Ridgeline,” Lance Woelfer, vice president of auto sales at American Honda Motor, told CNBC. “But one of the things that we want to bring forward in the future is increased ruggedness of that vehicle, even more capability.”

Woelfer declined to comment on whether the more rugged capability will include the vehicle moving from a car-based production process to a more traditional truck assembly, known as “body-on-frame,” which is how most trucks are built in the U.S.

Advertisement

Honda on July 23, 2026, released a teaser image of its next-generation Ridgeline pickup truck for the U.S. market.

COurtesy Honda

“That’s been an important part of its history. Whether or not it’s part of its future, I won’t get into that,” Woelfer said. “This is a step forward for the Ridgeline that I think everybody will appreciate.”

Expanding the capability of the Ridgeline, which is more known for smooth driving than ruggedness, could assist in expanding the vehicle’s buyers.

Advertisement

Sales of the Ridgeline were down about 3% during the first half of the year. The company has sold between roughly 41,000 and 52,000 Ridgelines annually since 2021. That compares with more than 270,000 units sold of the segment-leading Toyota Tacoma in 2025.

Honda’s confirmation of the new pickup comes as its CR-V compact crossover led U.S. auto sales through the first half of the year for the first time ever.

CR-V sales increased roughly 6% compared with last year as the Ford F-Series pickups and Toyota Rav4 crossover, which have led sales in recent years, dealt with production bottlenecks.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Advertisement
Continue Reading

Trending

Copyright © 2025